Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta‐analysis

Review of 12 studies (5,829 patients with CYP2C19 loss‐of‐function alleles) found those given ticagrelor or prasugrel had a lower risk of MACE (RR=0.52), CV death (0.41), all cause death (0.44) and stent thrombosis (0.55) than those who received clopidogrel (all p<0.05).

SPS commentary:

Major and minor bleeding risk was not significantly different between groups.  Authors conclude that CYP2C19 reducedÔÇÉmetabolisers can expect better clinical outcome on using prasugrel or ticagrelor rather than clopidogrel.

Source:

British Journal of Clinical Pharmacology